This study, called TENACITY-01, is testing a treatment called CTD402 CAR T Cell Injection for people with T-cell Acute Lymphocytic Leukemia (T-ALL) or Lymphoblastic Lymphoma (LBL) that has come back or not responded to previous treatments. The main goals are to see if CTD402 is safe and how well it works. You might be able to join if you are 12 years or older, weigh at least 40 kilograms, and have T-ALL/LBL that has relapsed or is refractory after two or more treatments, or if your first relapse happened within 12 months of your first remission. The study plans to enroll 54 participants and is currently unclear if it is recruiting.

Study design

This is a single-arm, open-label study, meaning all participants receive the same treatment and everyone knows what treatment is being given. It will enroll about 54 participants in two phases to assess the safety and effectiveness of CTD402.

What's involved

You would receive one infusion of CTD402 after a period of chemotherapy. You will be followed for up to 24 months in this study, and then for up to 15 years under a separate long-term follow-up protocol.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 24 months within this study, and then for up to 15 years under a separate long-term follow-up protocol to monitor survival, side effects, and other health outcomes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.